ACRO is a leading voice for safe and ethical clinical trials, working with stakeholders globally to explore new paradigms for research and development and to promote a better and more efficient clinical trial process. As such, the association looks to actively engage in EFGCP by supporting its mission and activities to ensure the highest ethical and scientific standards in clinical research globally.

The Belgian Chapter (ACRP.be) brings the European regulations and the ACRP's educational benefits to local levels. The Chapter events are open to ACRP members and non-members.

The CIEC (Clinical Investigation Center of CRP-Santé) is acting as a national center coordinating the activities of clinical research involving clinicians in various medical fields. CIEC is also supporting researchers aiming to consolidate their fundamental and experimental findings by clinical data. The main objectives of the CIEC are to promote clinical research and to assist & support clinical research projects in Luxembourg in the respect of ICH - GCP and Quality Assurance. Therefore the CIEC may provide any kind of logistic & clinical support to hospitals, physicians or other external partners interested in clinical trials. The CIEC is also a contact partner for the pharmaceutical industries interested in conducting clinical trials in Luxembourg. In addition, the CIEC is building a national clinical research network including clinicians and physicians in various medical fields in order to react in a timely manner to demands emanating from potential sponsors. The CIEC is striving to ensure respect of patient rights and patient data privacy, while offering the opportunity to access new and innovative therapeutic approaches that would not be accessible otherwise.

Mission statement:
The mission of CIEC is to promote clinical research according to Good Clinical Practice (ICH-GCP) and is therefore in line with the purpose of EFGCP. EFGCP and CIEC share their interests in conducting clinical research according to high quality standards.

In responding to HIV, EATG considers diseases frequently seen as co-infection in people with HIV, as well as other health issues that increase the risk of HIV of prime importance. In the past few years EATG has increased its activities on co-infectionssuch as hepatitis C, hepatitis B and tuberculosis.
Our primary geographic focus is member states served by the World Health Organisation (WHO) Regional Office for Europe. However, European AIDS Treatment group considers all potential opportunities for collaboration and support of similar efforts in other parts of the world. Access to the best available treatments is a major goal for the EATG. This includes:
• Access to all people who could benefit from the treatment, including so-called 'sub-populations' like drug-users, women, children, migrants, people with hepatitis or tuberculosis co-infection, with haemophilia and other.
• Access for patients in all stages of HIV infection (including first-line, salvage)
• Access to treatment in all European countries.

The EBMT coordinates its scientific activities through its working parties. The majority of which are disease‐based: Acute Leukaemia, Severe Aplastic Anaemia, Autoimmune Diseases, Chronic Malignancies, Inborn Errors, Lymphomas and Solid Tumours. The others have scientific activities across varied diseases: Immunobiology, Infectious Diseases, Transplant-related Complications and Quality of Life after SCT, and Paediatrics). Those working parties perform retrospective and non-interventional prospective studies. In addition, they conduct academic prospective clinical trials, which form a key part of patient-oriented clinical research, and create the basis for continuously improving patient care.
The EBMT shares the EFGCP mission to improve the ethical and scientific standards of clinical research and sees the benefits of working with other European organisations to promote the interests of patients. Through international cooperation and application of Good Clinical Practice, patient safety and clinical data quality can be assured, which is the ultimate aim of our clinical trials.

ECRIN connects national networks and hubs of clinical research centres and clinical trial units, allowing for provision of coordinated services to multinational studies, through European Correspondents (EuCo) hosted in the national hub, acting as the single contact point in each country. The ECRIN network currently covers 14 European member states or associated countries, progressively expanding to other countries, and ECRIN also develops connections with other world regions.

By establishing a consistent organisation for clinical research in Europe, ECRIN:
- fosters the development of the national clinical research capacity in line with EU standards, thus raising the attractiveness for multinational investigator-driven or industry-sponsored clinical trials
- enables access to competence centres conducting clinical studies with high quality standards and professional staff
- fosters initiation of, and participation in multinational clinical research projects
- contributes to the promotion of a harmonised regulatory system and ethical standards
- creates a common culture by sharing procedures, tools, practice, and trains a new generation of research professionals
- fosters the involvement of patients and citizens, promoting transparency and data sharing
- promotes mechanisms for funding multinational clinical research projects
- promotes the structuring of pan-European disease-oriented investigation networks.

ECRIN and EFGCP share common interests to disseminate EU standards to conduct clinical research for the benefit of patient. They have been collaborating on various projects and initiatives related to European clinical research, including the ICREL project, and the Roadmap Initiative for Clinical research in Europe.

The role of pragmatic data and related methodology need to be developed within multi-stakeholder platforms, and with this goal in mind, the EORTC participates in projects such as those put forth by the Innovative Medicines Initiative. Such activities make the EORTC one of Europe’s leading players in transforming experimental discoveries into new treatments with a significant clinical impact.

Alongside its own scientific and clinical program, the EORTC collaborates with a number of research institutions including the US National Cancer Institute and many other national and international research groups worldwide.

A new model of partnership with the pharmaceutical industry and all stakeholders is under consideration facing the current challenges of drug development and the complexity of clinical research.

Funders of the EORTC include the EORTC Charitable Trust (with the support of national cancer leagues), the “Fonds Cancer�, private donations and corporate sponsorship, the Belgian National Lottery, and, for specific research projects, the European Commission. Since the early 1970’s, EORTC headquarters has received continuous support from the US National Cancer Institute (NCI).

The EFGCP and the EORTC share common interests and have worked together developing and conducting workshops and conferences promoting good clinical practice.

The aims of the Society are:
- To promote exchange of information between European anaesthesiologists,
- To disseminate information in regard to anaesthesiology,
- To raise the standards of the speciality by fostering and encouraging education, research, scientific progress and exchange of information,
- To promote and protect the interest of its members,
- To promote improvements in safety and quality of care of patients who are under the care of anaesthesiologists inside and outside the operating room by facilitating and harmonising the activities of national and international societies of anaesthesiologists in Europe.

ESA is also establishing a Clinical Translational Research Network (CTN) in order to provide an infrastructure that allows improving the care of patients in the fields of anaesthesia, pain, intensive care and emergency medicine through transnational European collaborative investigations. The ESA CTN is managed by the ESA Research Committee in collaboration with the ESA Scientific Programme Committee and the National Anaesthesia Societies Committee, and will report to the ESA Board for its actions and activities.

ESA is organising the European Diploma in Anaesthesiology and Intensive Care Medicine (EDA) throughout Europe in 11 European languages in more than 20 Examination centres. It is a multilingual, end-of-training, two-part examination covering the relevant basic sciences and clinical subjects appropriate for a specialist anaesthesiologist. In Several European countries, the EDA Part I Exam is a mandatory Exam for the specialisation of Anaesthesiologist.

Finally, ESA organises the European Anaesthesiology Congresses throughout Europe under the banner EUROANAESTHESIA. These meetings are attended by members and non-members representing more than 80 countries from around the world. The European Anaesthesiology Congresses offer a comprehensive scientific programme of refresher course lectures, symposia and workshops, together with presentation and discussion of the latest research undertaken in Europe in particular. The European Anaesthesiology Congresses are accredited by the U.E.M.S./EACCME for C.M.E. credits. More than 6000 delegates attend the congress every year and more than 100 exhibitors participate in the industrial exhibition at the Euroanaesthesia Annual Meeting each year.

ESA choose to join the EFGCP to access to the leading European and international discussions on ethics and science in clinical research, to facilitate the transfer of knowledge and skills across disciplines and sectors, and to enhance cooperation through networking and partnerships opportunities within the clinical research community.

In the EU there are more than 25 million people living with diabetes (around 50 million across Europe as a whole). The challenge to the diabetes stakeholder community is to respond with coordinated research that can be translated into effective treatments. While support from the European Commission (EC), member states’ funding agencies and private foundations plays an important role in advancing research there is still a lack of information on research gaps and research overlap.

Through the DIAMAP project EURADIA has coordinated expert focussed groups to identify gaps and highlight strengths, to guide a Road Map strategy for diabetes research in Europe. EURADIA has incorporated the DIAMAP Road Map strategy into its mission to improve the lives of people with diabetes, membership in the European Forum for Good Clinical Practice is integral to diabetes finding a specific voice within the clinical research community.

GIMEMA has come a long way since then. Today it is a recognized non-profit Foundation which operates, through its various bodies, to promote the activities of the group, whose objectives are threefold: a) Cultural, guaranteeing equal treatment to all patients, notwithstanding their geographical origin, sharing know-how through regular scientific meetings and assuring all treatment protocols, not only research ones, adopt a national standard and enforcing a national biological samples centralization laboratory network; b) Scientific, through research activities and conduction of clinical trials, where the GIMEMA Foundation is a main actor in the regulatory decision-making process enforced by AIFA (Italian Medicines Agency) and c) Educative, by means of targeted training courses aimed at contributing to the national know-how in terms of no-profit research.
Clinical research projects are thus entrusted to the GIMEMA operational centre, the Data Centre, which manages the development and running of clinical trials in accordance with the complex regulations in force. And which has been awarded the UNI EN ISO 9001:2000 Certificate for the "Design, conduction and management of clinical trials". Its organizational structure means it also boasts complex centralized diagnosis capabilities, enabling all Italian GIMEMA Centres to offer patients the same level of diagnosis and treatment, irrespective of where they are in the country.
The Foundation is administered by a Governing Council made up of a minimum of three and a maximum of nine members. The Governing Council has all ordinary and extraordinary administration powers.
The Governing Council is responsible for:
- decisions regarding applications for inclusion or exclusion of new Associate Member Centres;
- preparation of the annual report and accounts;
- decisions regarding general criteria relating to the Foundation’s activities and, in particular, those regarding study, information, documentation and disclosure, as well as all other initiatives necessary for the Foundation to fulfil its objectives.
The Scientific Committee, upon request of the Governing Council:
- identifies areas of interest for the Foundation’s activities and sets up study commissions on the topics deemed most relevant;
- puts forward new studies, which it allocates to interested researchers who act as protocol coordinators, either alone or in collaboration;
- evaluates new study proposals from Members of the Group, identifies which studies are to be conducted and approves biological, clinical and/or social research protocols written by the various coordinators;
- promotes and maintains scientific contacts with the Italian Association of Haematology and with other national and international organizations involved in the research and treatment of haematological diseases;
- produces an annual report, in collaboration with the Data Centre, on the activities of the Foundation;
- reviews scientific manuscripts written and proposed by the GIMEMA Group before being submitted for publication.
GIMEMA Foundation is a leading Italian organization for conduction of clinical trials in haematology. As such, the Foundation is actively interested in EFGCP activities which translate into an stimulating environment that can actively support the fulfilment of the Foundation’s main objective, that of improving haematology therapeutic approaches throughout clinical trials.

Strategic Objectives

MMI is leading on the establishment of the Irish Clinical Research Infrastructure Network (ICRIN) which aims to enable the efficient conduct of academic and commercial clinical trials and other research activities; to represent Ireland in the European Clinical Research Infrastructure Network (ECRIN); to continue to deliver general and bespoke training and support processes on good research practices and to foster new clinical development activity in indigenous innovators and SMEs and to promote Ireland externally as a place to perform relevant clinical research.
MMI support EFGCP as they provide an independent forum enabling pragmatic engagement of all clinical research stakeholders to propose solutions to the challenges in conducting research activities more effectively in Europe.